FDA Approves Bevacizumab Biosimilar

June 28, 2019 – The FDA has approved PF-06439535 (bevacizumab-bvzr), a bevacizumab biosimilar for the treatment of patients with metastatic carcinoma of the colon or rectum; unresectable advanced, metastatic, or recurrent non–small cell lung cancer (NSCLC); advanced and/or metastatic renal cell cancer, and persistent recurrent or metastatic carcinoma of the cervix. “Biosimilars like bevacizumab-bvzr can help increase access to impactful therapies, driving market … (leggi tutto)